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Abstract
Introduction: Insulin resistance is defined as reduction of insulin-stimulated glucose uptake in skeletal muscles and inadequate suppression of 
the production of endogenous glucose. The aim of this study was to assess the effect of vitamin D intake on insulin resistance in aged patients.
Materials and methods: This interventional study was carried out on residents of Sadeghieh Nursing Home in Iran. The participants 
were healthy adults aged ≥ 65. For eight weeks, the participants took pills containing 50,000 IU vitamin D3 per week. Insulin resistance 
was defined as homeostasis model assessment of insulin resistance (HOMA-IR) > 2.5. We used McNemar’s test, Wilcoxon test, chi-square, 
and Pearson correlation coefficient and SPSS software (v. 12) to analyse the collected data.
Results: The average age of the 76 participants was 78.7 ± 8 years and 52 of the participants were female. Before and after the study, 
37 and four participants had vitamin D deficiency, respectively (p < 0.001). Impaired fasting plasma glucose (FPG) and insulin resistance 
was not more prevalent in the participants with vitamin D deficiency. In this study, vitamin D intake had no significant effect on FPG level 
(p = 0.9), but it increased the prevalence of insulin resistance significantly (p < 0.001).
Conclusions: In our study, before and after the intervention, vitamin D deficiency had no relationship with FPG level and insulin resistance. Vita-
min D intake had no significant effect on FPG level, but it increased the prevalence of insulin resistance significantly. We believe that performing 
more studies, with a longer timespan and larger sample size, as double-blind clinical trials, is necessary. (Pol J Endocrinol 2012; 63 (3): 191–195)
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Streszczenie
Wstęp: Insulinooporność określa się jako zmniejszony insulinozależny wychwyt glukozy w mięśniach szkieletowych i niedostateczną supresję endo-
gennej produkcji glukozy. Celem niniejszego badania była ocena wpływu stosowania witaminy D na insulinooporność u osób w podeszłym wieku.
Materiał i metody: To kliniczne badanie eksperymentalne przeprowadzono u osób przebywających w placówce opiekuńczo-leczniczej 
Sadeghieh Nursing Home w Iranie. Uczestnicy byli zdrowymi osobami dorosłymi w wieku ≥ 65 lat. Przez 8 tygodni podawano im witaminę D3 
w kapsułkach w dawce 50 000 jm./tydzień. Insulinooporność definiowano jako wskaźnik HOMA-IR > 2,5. W ramach analizy statystycznej 
danych przeprowadzono testy McNemara, Wilcoxona, c2 i określono współczynnik korelacji Pearsona, używając programu SPSS (wersja 12).
Wyniki: Średni wiek 76 uczestników badania (52 kobiety) wynosił 78,7 ± 8 lat. Niedobór witaminy D przed badaniem stwierdzono 
u 37 osób, a w trakcie badania — u 4 osób (p < 0,001). Nieprawidłowa glikemia na czczo (FPG, fasting plasma glucose) i insulinooporność nie 
występowały częściej u uczestników badania z niedoborem witaminy D. W niniejszym badaniu przyjmowanie witaminy D nie wpływało 
istotnie na FPG (p = 0,9), jednak powodowało istotne zwiększenie częstości insulinooporności (p < 0,001).
Wnioski: W niniejszym badaniu nie wykazano zależności między niedoborem witaminy D przed i w trakcie badania a FPG i insulinoopor-
nością. Suplementacja witaminy D nie wpłynęła istotnie na wartości FPG, jednak spowodowała zwiększenie częstości insulinooporności. 
Zdaniem autorów konieczne jest przeprowadzenie kolejnych badań metodą podwójnie ślepej próby, o dłuższym okresie obserwacji 
i o większej liczebności próby. (Endokrynol Pol 2012; 63 (3): 191–195)
Słowa kluczowe: insulinooporność, cukrzyca typu 2, witamina D
Introduction
Insulin resistance is defined as reduction of insu-
lin-stimulated glucose uptake in skeletal muscles and 
inadequate suppression of the production of endoge-
nous glucose. These are critical for maintaining normal 
glucose homeostasis [1]. Genetic and environmental 
factors implicate insulin resistance aetiology [2]. Insulin 
resistance plays an important role in the development of 
type 2 diabetes (T2D) [3–7]. T2D has reached epidemic 
proportions: worldwide, more than 160 million indi-
viduals are diagnosed with this disease [8].
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Insulin secretion is influenced by vitamin D. Vitamin 
D increases the concentration of intracellular calcium 
via non-selective voltage-dependent calcium channels 
and thus influences the secretion of insulin by b-cell [9]. 
Many studies have suggested that vitamin D deficiency 
may be one of the factors participating in the develop-
ment of insulin resistance. The relationship between 
vitamin D and insulin resistance has been reported in the 
early stages of chronic kidney disease [10], in a paediatric 
population at risk of diabetes [11], and in adults without 
physician-diagnosed diabetes in the United States [12]. But 
some studies have reported that there was no association 
between vitamin D and insulin resistance [13–15].
Also, the effect of vitamin D intake on insulin resist-
ance is controversial. For example, vitamin D intake 
in T2D patients (as fortified yogurt) [16] and among 
participants with impaired fasting blood glucose (FBG) 
[17] improved insulin resistance. But vitamin D intake in 
T2D patients (as sub-therapeutic vitamin D treatment) 
[18], in Indian patients with moderately controlled T2D 
[19], and among participants with normal FBG [17], did 
not improve insulin resistance.
In light of the controversy about the effect of vitamin 
D intake on insulin resistance, we decided to determine 
whether vitamin D treatment improves insulin resist-
ance in aged nursing home residents.
Materials and methods
This interventional prospective study was done on resi-
dents of Sadeghieh Nursing Home in Isfahan province 
in Iran. This trial was conducted by Isfahan University of 
Medical Sciences. The participants were healthy adults 
aged ≥ 65 who agreed to participate in the study. Exclusion 
criteria were: diabetes mellitus, consumption of drugs that 
could change glucose, insulin or vitamin D level, consump-
tion of vitamin D supplements in the two months prior 
to the study, and occurrence of a severe or acute disease 
during the study. The participants’ diet was unchanged 
before and throughout the study. Demographic data 
was collected via a questionnaire. For eight weeks, the 
participants took pills containing 50,000 IU vitamin D3 
per week. Before and after vitamin D consumption, to 
evaluate Fasting Plasma Glucose (FPG), insulin, 25-hy-
droxy vitamin D (25(OH)D), calcium (Ca), phosphorus 
(P), parathyroid hormone (PT H) and albumin, 10 cc 
blood samples were gathered from each participant. The 
samples were collected in the morning in a fasting state. 
All the samples were gathered by an expert and evaluated 
in the endocrinology research centre laboratory of Isfahan 
University of Medical Sciences. Insulin resistance was 
measured by homeostasis model assessment of insulin 
resistance (HOMA-IR). HOMA-IR is one of the indices of 
insulin resistance [2, 7, 20], and one study has reported 
that HOMA-IR is the best predictor of insulin resistance 
[20]. HOMA score is calculated using the formula: fasting 
glucose (mg/dL) ×fasting insulin (µU/mL)/405. Insulin 
resistance was defined as HOMA-IR > 2.5. Vitamin D 
deficiency was defined as < 8 ng/mL. 25(OH)D, PTH, 
and insulin were measured with enzyme-linked immu-
nosorbent assay (ELISA, IDS-iSYS 25-hydroxy vitamin 
D, Immunodiagnostic Systems, Boldon, UK), immuno-
radiometric assay (IRMA, Immunotech, Prague, Czech 
Republic), and enzyme-linked immunosorbent assay 
(ELISA, Monobind, Lake Forest, CA, USA), respectively. 
FPG, Ca, P, and albumin were measured with enzymatic 
methods (Pars azmoon, Iran).
We used McNemar’s test, Wilcoxon test, chi-square, 
and Pearson correlation coefficient to analyse the col-
lected data. p values < 0.05 (two-sided) were regarded 
as statistically significant. The statistical analyses were 
done using SPSS software, v. 12.
Results
The average age of the 76 participants was 78.7 ± 8 years 
(mean ± SD) and 52 participants (68.4%) were female. 
The participants’ ages were between 65 and 100 years. The 
participants were divided into subgroups according to age: 
65–75 (Group A), 75–85 (Group B) and > 85 (Group C). 
There were 25 participants in Group A of whom 14 (56%) 
were female. In Group B, there were 28 participants of 
whom 19 (67%) were female. There were 23 participants 
in Group C of whom 19 (82%) were female.
Before the study, 37 participants (48.7%) had vitamin 
D deficiency. After the intervention, the mean 25(OH)
D level significantly decreased (p < 0.001); it was seen 
in four participants (5.3%) (Table I). Before and after 
the intervention, there were no significant differences 
in vitamin D deficiency between the age groups or 
between female and male participants.
Before the study, 54 participants (71.1%) had nor-
mal FPG (FPG < 100 mM). After the intervention, 
55 participants (72.4%) had normal FPG. Before and 
after the intervention, the mean FPG level was 97.4 ± 35 
and 97.9 ± 37.5 mM, respectively, and there was no 
significant difference between them (p = 0.9) (Table II). 
Before and after the intervention, there were no signifi-
cant differences in FPG levels between the age groups 
or between female and male participants.
Before the study, ten participants (13.2%) had insulin 
resistance. After the intervention, 28 participants (36.8%) 
had insulin resistance. Before and after the interven-
tion, the mean HOMA-IR level was 1.34 ± 1.39 and 
3.72 ± 5.27, respectively, and there was a significant 
difference between them (p < 0.001) (Table III). Before 
and after the intervention, there was no significant 
difference between HOMA-IR levels in the age groups. 
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Table I. The prevalence of vitamin D deficiency, before and after the intervention, in the age groups
Tabela I. Częstość niedoborów witaminy D przed i po terapii w poszczególnych grupach wiekowych
Age group 25(OH)D level before the intervention [ng/mL] 25(OH)D level after the intervention [ng/mL]
Normal Deficient Normal Deficient
65–75 years 11 (44%) 14 (56%) 24 (96%) 1 (4%)
75–85 years 16 (57.1%) 12 (42.9%) 27 (96.4%) 1 (3.6%)
> 85 years 12 (52.2%) 11 (47.8%) 21 (91.3%) 2 (8.7%) 
Total 39 (51.3%) 37 (48.7%) 72 (94.7%) 4 (5.3%)
Vitamin D deficiency was defined as < 8 ng/mL
Table II. The FPG level, before and after the intervention, in the age groups
Tabela II. Wartości FPG przed i po terapii w poszczególnych grupach wiekowych
Age group FPG level before the intervention [mM] FPG level after the intervention [mM]
Normal FPG Impaired FPG Normal FPG Impaired FPG
65–75 years 18 (72%) 7 (28%) 18 (72%) 7 (28%)
75–85 years 20 (71.4%) 8 (28.6%) 21 (75%) 7 (25%)
> 85 years 16 (69.6%) 7 (30.4%) 16 (69.6%) 7 (30.4%)
Total 54 (71.1%) 22 (28.9%) 55 (72.4%) 21 (27.6%)
Impaired FPG was defined as FPG > 100 mM
Table III. Insulin resistance, before and after the intervention, in the age groups
Tabela III. Insulinooporność przed i po terapii w poszczególnych grupach wiekowych
Age group Insulin resistance before the intervention Insulin resistance after the intervention
Normal insulin status [IU/mL] Insulin resistance [IU/mL] Normal insulin status [IU/mL] Insulin resistance [IU/mL]
65–75 years 19 (76%) 6 (24%) 16 (64%) 9 (36%)
75–85 years 25 (89.3%) 3 (10.7%) 17 (60.7%) 11 (39.3%)
> 85 years 22 (95.7%) 1 (4.3%) 15 (65.2%) 8 (34.8%)
Total 66 (86.8%) 10 (13.25) 48 (63.2%) 28 (36.8%)
Insulin resistance was defined as HOMA-IR > 2.5
Table IV. Effect of vitamin D supplementation on changes of study parameters
Tabela IV. Wpływ suplementacji witaminy na zmiany badanych parametrów
Before the intervention After the intervention p value
Number 76 76 –
Insulin [IU/mL] 5.2 ± 4.3 13.1 ± 15 < 0.001
Ca [mmol/L] 7.6 ± 0.9 8.4 ± 0.6 < 0.001
P [mmol/L] 3.6 ± 0.3 4.1 ± 0.4 < 0.001
PTH [pg/mL] 81 ± 98.1 41.1 ± 62.5 < 0.001
Albumin [g/L] 3.7 ± 0.4 4.3 ± 0.5 < 0.001
Ca — calcium; P — phosphorus; PTH — parathyroid hormone
Before the intervention, insulin resistance in the male 
participants was significantly more than in the females 
(p = 0.005): seven male participants (29.2%) versus three 
female participants (5.8%). But after the intervention, 
there was no significant difference between HOMA-IR 
levels in the male and female participants.
The amount of insulin, Ca, P, PTH and albumin, 
before and after the intervention, is shown in Table IV. 
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After the intervention, insulin, albumin, Ca and P serum 
levels increased significantly. But serum level of PTH 
after the intervention decreased significantly.
Before the intervention, there was no relationship 
between vitamin D deficiency with FPG level and in-
sulin resistance. Also, after the intervention, there was 
no relationship between vitamin D deficiency with FPG 
level and insulin resistance.
Discussion
Type 2 diabetes is a worldwide disease and insulin 
resistance plays an important role in its development 
[3–7]. The relationship between insulin resistance and 
vitamin D deficiency is controversial. Also, in different 
studies, insulin intake has been found to have different 
effects on insulin resistance.
In this study, the prevalence of vitamin D deficiency 
in aged persons was 48.7%, and this is in accord with 
similar studies done on aged persons [22–24]. According 
to previous studies, the prevalence of hypovitaminosis 
D is between 30% and 90% in developing countries, and 
old age has been reported as a risk factor for hypovita-
minosis D [22]. In our study, insulin resistance before the 
intervention in the male participants was significantly 
more than in the females. This is in accord with Gay-
oso-Diz et al.’s study, which reported that HOMA-IR 
levels in men were higher than in women [25].
Our study showed that impaired FPG and insulin 
resistance were not more prevalent in the participants 
with vitamin D deficiency. Our results are consistent 
with Vilarrasa et al.’s study findings, which reported no 
associations between 25(OH)D and plasma glucose and 
insulin resistance in patients with morbid obesity [13]. Also, 
our results are in accord with Muscogiuri et al.’s findings 
in obese individuals [14] and Gulseth et al.’s findings in 
European subjects with metabolic syndrome [15].
In the present study, we found that consumption 
of 50,000 IU vitamin D3 per week supplements has no 
significant effect on FPG, but it can increase insulin 
resistance significantly. These findings are consistent 
with Pittas et al.’s study results. Pittas reported that in 
Caucasian adults with impaired fasting glucose, daily 
consumption of 700 IU vitamin D and Ca for three years 
might attenuate increases in insulin resistance [17]. Our 
findings are not in accord with Nikooyeh et al.’s study, 
which reported that daily intake of a vitamin D-fortified 
yogurt drink (containing 500 IU vitamin D3) twice a day 
for 12 weeks improved glycaemic status and insulin 
resistance in type 2 diabetes patients [16]. Furthermore, 
the results of our study and Von Hurst et al.’s study are 
not similar. Von Hurst reported that daily intake of 4,000 IU 
vitamin D3 for six months improved insulin resistance 
in insulin resistant South Asian women [25].
The findings of Patel et al.’s study are different from 
our results. That study was done on type 2 diabetes 
patients and showed that four-month consumption 
of 1,200 IU daily of vitamin D (a subtherapeutic dose) 
had no significant effect on insulin resistance [18]. This 
difference may be due to the difference between doses 
of vitamin D in the studies. Also, Parekh et al, found 
that four-week consumption of vitamin D in 28 Indian 
patients with moderately controlled type 2 diabetes 
mellitus was not associated with improvement in insu-
lin secretion or insulin sensitivity [19]. The difference 
between this study and our study results could be due 
to the timespan of this study.
Conclusion
In our study, before and after the intervention, vitamin 
D deficiency had no relationship with FPG level and 
insulin resistance. We found that vitamin D intake had 
no significant effect on FPG level, but it increased the 
prevalence of insulin resistance significantly. We believe 
that performing more studies, with a longer timespan 
and larger sample size, as double blind clinical trials, 
is necessary.
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